SynCardia Facebook SynCardia Twitter SynCardia LInkedIn SynCardia Google Plus SynCardia Youtube

SynCardia Systems, Inc.

Press Release:

Intermountain Medical Center Uses SynCardia Total Artificial Heart to Bridge 31-Year-Old Father to a Heart Transplant

Total Artificial Heart Was Only Option to Save Patient with Extensive Thrombus in Left Ventricle

 

February 2012: SynCardia Total Artificial Heart recipient Andrew Weaver, his wife Heather and their daughter Haley right before he was first diagnosed with heart problems.

TUCSON, Ariz. – March 21, 2013 – SynCardia Systems, Inc., manufacturer of the world’s first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that Andrew Weaver, a 31-year-old husband and father of one who arrived at Intermountain Medical Center in Salt Lake City in grave condition, has been successfully bridged to a heart transplant with the SynCardia temporary Total Artificial Heart and discharged home.

“We had several concerns when Andrew first came to us,” said Dr. Bruce Reid, surgical director of the Intermountain Medical Center Artificial Heart Program. “He had extensive thrombus in the left ventricle and profound biventricular failure. To use an LVAD would’ve been a very dangerous situation fraught with a high risk of stroke. It was for that reason we felt the best course of action was to replace his heart with the Total Artificial Heart.”

Mr. Weaver was born with a congenitally malformed aortic valve, and developed an aneurysm of the ascending aorta. However, these abnormalities were unknown until last February. Over time, his chest pains got increasingly worse. In October, he underwent surgery at a local hospital to have his aorta and aortic valve replaced, but was unable to be weaned from cardiopulmonary bypass. When his heart wouldn’t start beating again, he was transferred to Intermountain Medical Center.

Feb. 25, 2013: SynCardia Total Artificial Heart recipient Andrew Weaver a month after his heart transplant with his surgeon Dr. Bruce Reid at Intermountain Medical Center.

“He arrived on ECMO [a machine that takes over the function of the heart and lungs] with an open chest in critical condition,” said Dr. Reid. “We kept him on ECMO for a few days hoping that he’d have some cardiac recovery, but he did not. We didn’t feel we could bridge him with anything less than a Total Artificial Heart.”

Mr. Weaver was implanted with the SynCardia Total Artificial Heart on Oct. 18, 2012. Over the next several months, hospital staff helped him regain his strength and improve his health so he could be listed for a heart transplant. On Jan. 7, he was added to the waiting list, and just five days later, he received his heart transplant. On Jan. 24, Mr. Weaver was discharged from the hospital with his new donor heart. He is currently enjoying life at home with his wife of three years Heather and their 17-month-old daughter Haley and has returned to his job as a supply chain specialist.

“Without the SynCardia Total Artificial Heart, my husband would not have lived, Haley would have grown up without her dad and I would have lost my best friend,” said Heather. “Having him home is the best thing in the world!”

###

About SynCardia Systems, LLC
SynCardia Systems, LLC in Tucson, Ariz., is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. For people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure), the SynCardia temporary Total Artificial Heart is used as a bridge to transplant, helping them survive until a matching donor heart becomes available. SynCardia also manufactures the Freedom® portable driver, which powers the temporary Total Artificial Heart and allows clinically stable patients to be discharged from the hospital to enjoy life at home while they wait for a heart transplant.

Follow SynCardia: Facebook | Twitter | LinkedIn | Google+

SynCardia Contact:
Janelle Drumwright, jdrumwright@syncardia.com, (520) 547-7463

 

Search offcanvas